BioCardia, Inc. (BCDA) Income Statement
BCDA 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsBCDA revenue and net income
BCDA profit margins
BCDA growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | −100.0% | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
BCDA quarterly EPS vs estimates
BioCardia beat the analyst EPS estimate in 6 of the last 8 quarters. Next report: November 11, 2026 (estimate $-0.15).
BCDA income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $58,000 | $477,000 | $1.4M | $1.0M | $145,000 | $710,000 | $625,000 | $479,000 | $576,000 |
| Cost of revenue | $505,000 | $4.4M | $7.7M | $11.9M | $640,000 | $4,000 | $358,000 | $517,000 | $690,000 | $746,000 |
| Gross profit | −$505,000 | −$4.3M | −$7.2M | −$10.5M | $375,000 | $141,000 | $352,000 | $108,000 | −$211,000 | −$170,000 |
| Research & development | $5.0M | $4.4M | $7.7M | $8.8M | $8.6M | $9.8M | $8.6M | $8.5M | $5.8M | $3.3M |
| Sales, general & admin | $3.3M | $3.7M | $4.4M | $4.4M | $5.1M | $5.9M | $6.0M | $5.8M | $6.4M | $4.1M |
| Total operating expenses | $7.8M | $3.7M | $4.4M | $13.3M | $13.0M | $15.7M | $14.6M | $14.2M | $12.2M | $7.4M |
| Operating income | −$8.3M | −$8.0M | −$11.6M | −$11.9M | −$12.6M | −$15.5M | −$14.2M | −$14.1M | −$12.4M | −$7.6M |
| Interest income | — | — | — | — | $9,000 | $21,000 | $87,000 | $118,000 | $95,000 | $3.0M |
| Interest expense | — | — | — | $6,000 | $9,000 | $3,000 | $112,000 | $118,000 | $95,000 | $1.7M |
| Income before taxes | −$8.2M | −$7.9M | −$11.6M | −$11.9M | −$12.6M | −$15.0M | −$14.7M | −$14.0M | −$12.3M | −$10.3M |
| Income taxes | — | −$7.9M | $243,105 | $6,000 | −$2,000 | $1,000 | $110,000 | −$115,000 | −$192,000 | $5.4M |
| Net income | −$8.2M | −$7.9M | −$11.6M | −$11.9M | −$12.6M | −$15.0M | −$14.7M | −$14.0M | −$12.3M | −$10.3M |
| EBITDA | −$7.7M | −$7.9M | −$11.5M | −$11.8M | −$12.6M | −$14.9M | −$14.5M | −$13.9M | −$12.2M | −$8.5M |
| EPS (diluted) | −$1.29 | −$1.83 | −$8.25 | −$7.66 | −$5.78 | −$21.65 | −$11.55 | −$9.97 | $14.96 | −$280.16 |
| Gross margin | — | −7,463.8% | −1,519.7% | −780.3% | 36.9% | 97.2% | 49.6% | 17.3% | −44.1% | −29.5% |
| Operating margin | — | −13,794.8% | −2,441.1% | −880.3% | −1,244.3% | −10,709.7% | −2,001.8% | −2,256.3% | −2,589.8% | −1,320.8% |
| Net margin | — | −13,700.0% | −2,425.8% | −881.1% | −1,243.4% | −10,347.6% | −2,071.7% | −2,237.9% | −2,569.5% | −1,789.9% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $58,000 | $3,000 | $55,000 | $13,000 | $357,000 |
| Cost of revenue | $124,000 | $124,000 | $185,000 | $107,000 | $1.4M | $1.5M | $1.4M | $108,000 | $800,000 | $1.2M | $1.2M | $1.9M |
| Gross profit | −$124,000 | −$124,000 | −$185,000 | −$107,000 | −$1.4M | −$1.5M | −$1.4M | −$108,000 | −$797,000 | −$1.2M | −$1.1M | −$1.5M |
| Research & development | $893,000 | $1.2M | $1.1M | $932,000 | $1.4M | $1.5M | $1.4M | $931,000 | $800,000 | $1.2M | $1.2M | $1.9M |
| Sales, general & admin | $730,000 | $1.0M | $885,000 | $552,000 | $683,000 | $1.2M | $906,000 | $825,000 | $852,000 | $1.1M | $941,000 | $1.1M |
| Total operating expenses | $1.5M | $2.1M | $1.8M | $1.4M | $683,000 | $1.2M | $906,000 | $1.6M | $852,000 | $1.1M | $941,000 | $1.1M |
| Operating income | −$1.6M | −$2.3M | −$2.0M | −$1.5M | −$2.1M | −$2.7M | −$2.3M | −$1.8M | −$1.6M | −$2.3M | −$2.1M | −$2.6M |
| Interest expense | — | — | — | — | — | — | — | — | — | — | $9,000 | — |
| Income before taxes | −$1.6M | −$2.3M | −$2.0M | −$1.5M | −$2.0M | −$2.7M | −$2.3M | −$1.7M | −$1.6M | −$2.3M | −$2.1M | −$2.6M |
| Income taxes | — | — | — | — | — | — | −$62,724 | — | — | $62,724 | $6,000 | $3,000 |
| Net income | −$1.6M | −$2.3M | −$2.0M | −$1.5M | −$2.0M | −$2.7M | −$2.3M | −$1.7M | −$1.6M | −$2.3M | −$2.1M | −$2.6M |
| EBITDA | −$1.5M | −$2.3M | −$2.0M | −$1.5M | −$2.0M | −$2.7M | −$2.3M | −$1.7M | −$1.6M | −$2.2M | −$2.1M | −$2.6M |
| EPS (diluted) | −$0.13 | −$0.21 | −$0.06 | −$0.24 | −$0.40 | −$0.59 | −$0.25 | −$0.61 | −$0.88 | −$0.09 | −$1.35 | −$1.80 |
| Gross margin | — | — | — | — | — | — | — | −186.2% | −26,566.7% | −2,156.4% | −8,792.3% | −424.4% |
| Operating margin | — | — | — | — | — | — | — | −3,027.6% | −54,966.7% | −4,136.4% | −16,030.8% | −727.7% |
| Net margin | — | — | — | — | — | — | — | −2,994.8% | −54,866.7% | −4,121.8% | −15,938.5% | −721.0% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in BCDA's financial statements (latest annual report filed March 24, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
BCDA financial results
BioCardia reported no revenue in fiscal year 2025 (ended December 31, 2025). It had a net loss of $8.2 million. Diluted earnings per share came to −$1.29.
See the BCDA stock overview for the latest quote and news, or the BCDA chart for price history and technical indicators.
BCDA income statement FAQ
Does BioCardia have revenue?
BioCardia reported no revenue for fiscal year 2025, which ended on December 31, 2025.
Is BioCardia profitable?
No. BioCardia reported a net loss of $8.2 million in fiscal 2025.
How much does BioCardia spend on research and development?
BioCardia spent $5.0 million on research and development in fiscal 2025.
What are BioCardia's earnings per share?
BioCardia earned $-1.29 per diluted share in fiscal 2025, compared with $-1.83 a year earlier.
When will BioCardia report its next earnings?
BioCardia is expected to report results for the quarter ending September 30, 2026 on November 11, 2026.
When does BioCardia's fiscal year end?
BioCardia's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 24, 2026.